Gatifloxacin | Zimar eye drops 0.3%, 5 ml
Special Price
$30.38
Regular Price
$38.00
In stock
SKU
BID467725
Latin name
Zimar
Zimar
Latin name
Zimar
Release form
Zimar. Eye drops.
Packaging
In a dropper bottle 5 ml. In a cardboard bundle 1 bottle.
Pharmacological action of
Gatifloxacin - 8-methoxy fluoroquinolone with 3-methylpiperazinyl substitution at position C7. The antibacterial effect of gatifloxacin is due to the inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an enzyme involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme that plays a key role in the separation of chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones, including gatifloxacin, differs from the mechanism of action of antibacterial drugs of the group of aminoglycosides, macrolides and tetracyclines, therefore, gatifloxacin can be active against pathogenic bacteria that are resistant to the antibiotics listed above, and they, in turn, can be active against pathogenic bacteria that are resistant to gatifloxacin. Cross-resistance has not been established between gatifloxacin and the antibiotics listed above.
In vitro studies have shown that gatifloxacin resistance develops as a result of multistage mutations and occurs at a frequency of 1x107 - 1x1010.
Gatifloxacin is active against most of the following bacterial strains, both in vitro and in clinical use: Aerobic gram-positive bacteria: Corynebacterium propinquum.
Staphylococcus aureus.
Staphylococcus epidermidis.
Streptococcus mitis.
Streptococcus pneumoniae.
Aerobic gram-negative bacteria: Haemophilus influenzae.
Pharmacokinetics
After instillation of 0.3% eye drops of gatifloxacin, the plasma concentration of gatifloxacin remains below the analytical determination threshold (5 ng / ml).
Indications
Treatment of bacterial conjunctivitis caused by drug-sensitive pathogens.
Contraindications
Hypersensitivity to gatifloxacin, other quinolones, as well as other components of the drug.
Children's age up to 1 year.
Caution: In patients receiving systemic quinolone drugs, including gatifloxacin. In this category of patients, serious, and, in some cases fatal, hypersensitivity reactions (anaphylactic reactions) were noted, in some cases after the first injection of the drug. Separate reactions were accompanied by cardiovascular failure, loss of consciousness, angioedema (including swelling of the larynx, pharynx or face), airway obstruction, shortness of breath, itching and urticaria.
Pregnancy.
Breastfeeding period.
In patients with a history of allergic reactions to other topical preparations containing gatifloxacin. There is extremely rare information about the development of Steven-Johnson syndrome after topical use of gatifloxacin. At the first sign of an allergic reaction, you should immediately stop taking the drug.
Use during pregnancy and lactation
Due to the lack of adequate and strictly controlled studies in pregnant women, Zimar should be used during pregnancy with caution, and only if the expected benefit to the mother outweighs the potential risk to the fetus.
It is confirmed that with topical use of gatifloxacin in the form of eye drops, the systemic plasma concentration is low, therefore, the effect on breast-fed children is not expected.
However, when prescribing the drug Zimar during lactation, breastfeeding should be discontinued for the period of treatment due to the fact that the excretion of the drug in breast milk with topical application has not been studied.
Composition of
In 1 ml of a solution of eye drops contains:
Active ingredient
Gatifloxacin 3.0 mg.
Excipients
Benzalkonium chloride 0.05 mg, disodium edetate dihydrate 0.1 mg, sodium chloride 8.6 mg, hydrochloric acid to pH 5.8-6.0, sodium hydroxide to pH 5.8-6.0, water up to 1 ml.
Dosage and Administration
Topically. The drug is instilled during wakefulness.
1st and 2nd day instill 1 drop in the affected eye every 2 hours, up to 8 times a day.
From day 3 to 7, instill 1 drop up to 4 times a day.
Side effects
From the organ of vision
Often - conjunctival irritation, increased lacrimation, keratitis, papillary conjunctivitis, chemosis, conjunctival hemorrhage, dry eye mucosa (dry eye syndrome), discharge from the eyes, eyes, swelling of the eyelids, redness of the eyes, decreased visual acuity.
From the nervous system
Often - a headache.
On the part of metabolism and nutrition
Often - a change in taste.
In the post-marketing period, the following adverse reactions were reported for Zimar (frequency unknown)
From the organ of vision
Blepharitis, hyperemia of the eyes and conjunctiva, impaired vision, itching in the eyes, swelling in the eye area (including corneal and conjunctival edema ), eye irritation, eye pain.
From the digestive system
Nausea.
On the part of the immune system
Hypersensitivity, anaphylactic reactions, and angioedema (including swelling of the larynx, oral cavity, and face).
From the respiratory system, chest and mediastinal organs
Dispnea.
From the skin and subcutaneous tissues
Itching (including generalized itching), rash, urticaria.
overdose
Symptoms: There is a theoretical possibility of an overdose of the drug Zimar when burying into the eyes.
Treatment: Removal of excess drug from the eye / eyes by washing with warm running water.
Storage conditions
Store at a temperature not exceeding 25 РC.
Expiration
2 years. After opening the vial - 28 days.
pharmacy terms with prescription
Dosage form
Dosage form
eye drops
Allergan, United States
Zimar
Release form
Zimar. Eye drops.
Packaging
In a dropper bottle 5 ml. In a cardboard bundle 1 bottle.
Pharmacological action of
Gatifloxacin - 8-methoxy fluoroquinolone with 3-methylpiperazinyl substitution at position C7. The antibacterial effect of gatifloxacin is due to the inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an enzyme involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme that plays a key role in the separation of chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones, including gatifloxacin, differs from the mechanism of action of antibacterial drugs of the group of aminoglycosides, macrolides and tetracyclines, therefore, gatifloxacin can be active against pathogenic bacteria that are resistant to the antibiotics listed above, and they, in turn, can be active against pathogenic bacteria that are resistant to gatifloxacin. Cross-resistance has not been established between gatifloxacin and the antibiotics listed above.
In vitro studies have shown that gatifloxacin resistance develops as a result of multistage mutations and occurs at a frequency of 1x107 - 1x1010.
Gatifloxacin is active against most of the following bacterial strains, both in vitro and in clinical use: Aerobic gram-positive bacteria: Corynebacterium propinquum.
Staphylococcus aureus.
Staphylococcus epidermidis.
Streptococcus mitis.
Streptococcus pneumoniae.
Aerobic gram-negative bacteria: Haemophilus influenzae.
Pharmacokinetics
After instillation of 0.3% eye drops of gatifloxacin, the plasma concentration of gatifloxacin remains below the analytical determination threshold (5 ng / ml).
Indications
Treatment of bacterial conjunctivitis caused by drug-sensitive pathogens.
Contraindications
Hypersensitivity to gatifloxacin, other quinolones, as well as other components of the drug.
Children's age up to 1 year.
Caution: In patients receiving systemic quinolone drugs, including gatifloxacin. In this category of patients, serious, and, in some cases fatal, hypersensitivity reactions (anaphylactic reactions) were noted, in some cases after the first injection of the drug. Separate reactions were accompanied by cardiovascular failure, loss of consciousness, angioedema (including swelling of the larynx, pharynx or face), airway obstruction, shortness of breath, itching and urticaria.
Pregnancy.
Breastfeeding period.
In patients with a history of allergic reactions to other topical preparations containing gatifloxacin. There is extremely rare information about the development of Steven-Johnson syndrome after topical use of gatifloxacin. At the first sign of an allergic reaction, you should immediately stop taking the drug.
Use during pregnancy and lactation
Due to the lack of adequate and strictly controlled studies in pregnant women, Zimar should be used during pregnancy with caution, and only if the expected benefit to the mother outweighs the potential risk to the fetus.
It is confirmed that with topical use of gatifloxacin in the form of eye drops, the systemic plasma concentration is low, therefore, the effect on breast-fed children is not expected.
However, when prescribing the drug Zimar during lactation, breastfeeding should be discontinued for the period of treatment due to the fact that the excretion of the drug in breast milk with topical application has not been studied.
Composition of
In 1 ml of a solution of eye drops contains:
Active ingredient
Gatifloxacin 3.0 mg.
Excipients
Benzalkonium chloride 0.05 mg, disodium edetate dihydrate 0.1 mg, sodium chloride 8.6 mg, hydrochloric acid to pH 5.8-6.0, sodium hydroxide to pH 5.8-6.0, water up to 1 ml.
Dosage and Administration
Topically. The drug is instilled during wakefulness.
1st and 2nd day instill 1 drop in the affected eye every 2 hours, up to 8 times a day.
From day 3 to 7, instill 1 drop up to 4 times a day.
Side effects
From the organ of vision
Often - conjunctival irritation, increased lacrimation, keratitis, papillary conjunctivitis, chemosis, conjunctival hemorrhage, dry eye mucosa (dry eye syndrome), discharge from the eyes, eyes, swelling of the eyelids, redness of the eyes, decreased visual acuity.
From the nervous system
Often - a headache.
On the part of metabolism and nutrition
Often - a change in taste.
In the post-marketing period, the following adverse reactions were reported for Zimar (frequency unknown)
From the organ of vision
Blepharitis, hyperemia of the eyes and conjunctiva, impaired vision, itching in the eyes, swelling in the eye area (including corneal and conjunctival edema ), eye irritation, eye pain.
From the digestive system
Nausea.
On the part of the immune system
Hypersensitivity, anaphylactic reactions, and angioedema (including swelling of the larynx, oral cavity, and face).
From the respiratory system, chest and mediastinal organs
Dispnea.
From the skin and subcutaneous tissues
Itching (including generalized itching), rash, urticaria.
overdose
Symptoms: There is a theoretical possibility of an overdose of the drug Zimar when burying into the eyes.
Treatment: Removal of excess drug from the eye / eyes by washing with warm running water.
Storage conditions
Store at a temperature not exceeding 25 РC.
Expiration
2 years. After opening the vial - 28 days.
pharmacy terms with prescription
Dosage form
Dosage form
eye drops
Allergan, United States
Write Your Own Review